GabrielCBrooksMDMAS FACC

Non-Invasive Cardiology

Executive Director, Head of Rare Cardiology, Rare Disease Research Unit, Pfizer Inc.

Dr. Brooks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of CaliforniaMAS, Clinical Research (Epi/Bio-Stats), 2013 - 2015
University of California (San Francisco)Fellowship, Cardiovascular Disease, 2011 - 2014
Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
Weill Cornell MedicineClass of 2008
Carnegie Mellon UniversityB.S., Biology, 1995 - 2001

PubMed

67 citations
Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.
Gabriel C. Brooks, Byron K. Lee, Rajni K. Rao, Feng Lin, Daniel P. Morin
Journal of the American College of Cardiology. 2016-03-15
71 citations
Accuracy and Usability of a Self-Administered 6-Minute Walk Test Smartphone Application
Gabriel C. Brooks, Eric Vittinghoff, Sivaraman Iyer, Damini Tandon, Peter Kuhar
Circulation. Heart Failure. 2015-09-01
163 citations
Relation of C-reactive protein to abdominal adiposity.
Gabriel C. Brooks, Michael J. Blaha, Roger S. Blumenthal
The American Journal of Cardiology. 2010-07-01

Journal Articles

Evaluation of myocardial fibrosis by post gadolinium T1 measurement in patients with pulmonary hypertension
Kallianos K, Higgins C, Odrovas K, J Cardiovasc Magn Reson, 1/1/2015
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus
Liu TC, Wang Y, Hallden G, Francis J, Lemoine NR, Kirn D., Gene Ther., 1/1/2005
Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer
Thorne SH, Lee YL, Au T, Eng LF, Reid T., J Virol, 1/1/2005
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency
Liu TC, Hallden G, Wang Y, Francis J, Lemoine N, Kirn D., Mol Ther., 1/1/2004
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Lemoine N, Kirn D., Nat Biotechnol, 1/1/2003
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise C, Hermiston T, Johnson L, Sampson-Johannes A, Williams A, Hawkins L, Kirn D, Nature Medicine, 1/1/2000
Join now to see all

Abstracts/Posters

The Association Between Clinical and Echocardiographic Imaging Findings and T2 in End Stage Liver Disease
Brown K, Mehta N, Rubin N, Foster E, Qasim A., American Heart Association, 1/1/2015
Evaluation of myocardial fibrosis by post gadolinium T1 measurement in patients with pulmonary hypertension
Kallianos K, Higgins C, Ordovas K., Society for Cardiac Magnetic Resonance, Nice, 1/1/2015
Diagnostic Accuracy of a Smartphone based Six-Minute Walk Test
Vittinghoff E, Sivaraman I, Marcus G, Olgin J, American Heart Association, 1/1/2014
Ets-2 acts in a common pathway with Tbx5 to regulate coronary blood vessel development
Diman N, Hatcher C, Basson C., American Heart Association, 1/1/2006
Selective replication and antitumoral efficacy with an E1A mutant adenovirus
Heise C, Hermiston T, Johnson L, Kirn D, American Association for Cancer Research, San Francisco, 1/1/2000
Adenoviral Mutants as novel therapeutic agents against cancer
Heise C, Hermiston T, Kirn D., International cancer gene therapy conference, San Diego, 1/1/1998
Join now to see all

Lectures

Classifying lung cancer stage from health care claims with a clinical algorithm or a machine-learning approach.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018